Special Drug Use Investigation for IMURAN (Azathioprine) Tablet (Pulmones Transplantation)

GlaxoSmithKline39 enrolled

Overview

This post-marketing surveillance study is to investigate the efficacy and safety of azathioprine tablets in subjects whom lung transplantation is performed.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Liver Diseases

Interventions

AzathioprineDRUG

At the start of treatment, 2 to 3 mg per kg of body weight each day. For the rest of treatment, 1 to 2 mg per kg of body weight each day.

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Subjects who undergo lung transplantation and azathioprine tablets were administered Exclusion Criteria: * Subjects with hypersensitivity to the ingredients of azathioprine tablet * Subjects who is pregnant or might be pregnant * Subjects whose white count is lower than 3000/cubic millimeter

Outcomes

Primary Outcomes

Incidence of adverse events related to azathioprine tablets

Time frame: 3 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.